Markets
Corvus Stock Soars 8.22% — Adding $67 Million Even With Eczema Results Delayed
The drug developer’s third-quarter loss widened to $20.3 million as research costs rose, with trial results expected in 2027.
CRVS
Corvus Pharmaceuticals (CRVS) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Corvus Spends $17.8 Million On Research As Soquelitinib Trials Expand Across Immune Diseases
The drug developer expects its $202.9 million cash pool to fund operations into the second quarter of 2028.
Earnings
Corvus Sets March 2027 For Angel's Atopic Dermatitis Data, Citing A Blinding Window
CEO Richard Miller says the wait keeps everyone blinded, and cash of $202.9 million should last into the second quarter of 2028.